Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial

  • Home
  • Company News
  • Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial
09Dec

Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial

 

Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in patients with ovarian cancer.

Out of 16 patients, one patient demonstrated a complete response and two patients experienced a partial response according to industry-standard RECIST criteria, making an overall response rate of 19 per cent.

The patient who experienced a complete response remains in remission some three years after her last dose of Cantrixil.

Shares in Kazia Therapeutics (ASX:KZA) are trading 4.4 per cent higher at $1.42.

 
Copyright 2020 – Finance News Network


Source: Finance News Network

Share this post

Related Posts

10Feb

LiveTiles (ASX:LVT) partners with Canva

10 Feb 2020 - Global software company LiveTiles (ASX:LVT) has partnered with Canva, the world’s leader in empowering people to create compelling, data-rich visuals.

Read More
12Feb

Spark Infrastructure’s (ASX:SKI) TransGrid raises $600m

12 Feb 2021 - Spark Infrastructure’s (ASX:SKI) TransGrid Services has secured $600 million via new five-year syndicated bank debt facilities.

Read More
11May

Magellan Minutes: Opportunities in the finance sector

11 May 2023 - Portfolio Manager Alan Pullen discusses the recent bank defaults, the impact of interest rates on banks in general and where he sees opportunities in the financial sector.

Read More
16Apr

Mayne Pharma (ASX:MYX) submits oral contraceptive FDA approval application

16 Apr 2020 - Mayne Pharma (ASX:MYX) has submitted a new drug application to the US Food and Drug Administration (FDA) its E4/DRSP oral contraceptive.

Read More
15Sep

Pilbara Minerals (ASX:PLS) achieve financial close for US$110m debt facility

15 Sep 2020 - Pilbara Minerals (ASX:PLS) has completed and executed the finance documents supporting the senior secured US$110M Finance Facility with BNP Paribas and the Clean Energy Finance Corporation (CEFC).

Read More
21Aug

a2 Milk (ASX:A2M) lobs NZ$270M offer for NZ facility

21 Aug 2020 - The a2 Milk Company is engaged in exclusive discussions with nutrition dairy business, Mataura Valley Milk with a view to participating in manufacturing at the facility in Southland, New Zealand.

Read More
02Apr

Rural Funds Management has been awarded damages over a Bonitas short sell report

02 Apr 2020 - Rural Funds Management as responsible entity for the Rural Funds Group (ASX:RFF) has been awarded damages over a Bonitas short sell report.

Read More
22Oct

Stocks of the Hour: Nanoveu, MoneyMe, Alicanto Minerals

22 Oct 2024 - A snapshot of the stocks on the move, featuring Nanoveu (ASX:NVU), MoneyMe (ASX:MME) and Alicanto Minerals (ASX:AQI).

Read More
03Nov

Stocks of the Hour: Findi, Immutep, ImpediMed

03 Nov 2023 - A snapshot of the stocks on the move, featuring Findi (ASX:FND), Immutep (ASX:IMM) and ImpediMed (ASX:IPD).

Read More
28Nov

IMF Bentham (ASX:IMF) reaches binding settlement agreement regarding Bellamy’s class action

28 Nov 2019 - Further to the announcement made on 5 November 2019 that an in-principle settlement of the securities class action against Bellamy’s Australia (ASX:BAL) had been reached, IMF Bentham (ASX:IMF) says it has progressed to an executed binding settlement agreement.

Read More